Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 1,602.8% in January

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 75,842 shares, an increase of 1,602.8% from the December 31st total of 4,454 shares. Based on an average daily trading volume, of 645,779 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 645,779 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Daiichi Sankyo presently has an average rating of “Moderate Buy”.

Daiichi Sankyo Price Performance

OTCMKTS:DSNKY traded down $0.40 during midday trading on Tuesday, hitting $19.85. 222,628 shares of the stock were exchanged, compared to its average volume of 350,142. The company has a market capitalization of $37.60 billion and a price-to-earnings ratio of 18.73. The company has a current ratio of 2.31, a quick ratio of 1.60 and a debt-to-equity ratio of 0.06. Daiichi Sankyo has a one year low of $19.71 and a one year high of $29.68. The business has a 50-day moving average price of $22.06 and a two-hundred day moving average price of $23.60.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.